- Home
- JLL vs ICLR Comparison
JLL vs ICLR Comparison
Compare JLL & ICLR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | JLL | ICLR |
|---|---|---|
| Founded | 1997 | 1990 |
| Country | United States | Ireland |
| Employees | N/A | N/A |
| Industry | Real Estate | Biotechnology: Commercial Physical & Biological Resarch |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 14.9B | 14.3B |
| IPO Year | 1997 | 1998 |
Fundamental Metrics
Financial Performance| Metric | JLL | ICLR |
|---|---|---|
| Price | $327.48 | $185.83 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 8 | 14 |
| Target Price | ★ $342.14 | $201.23 |
| AVG Volume (30 Days) | 306.0K | ★ 1.0M |
| Earning Date | 11-05-2025 | 10-22-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 31.91 | N/A |
| EPS | ★ 13.05 | 7.47 |
| Revenue | ★ $25,317,800,000.00 | $8,102,602,000.00 |
| Revenue This Year | $11.77 | N/A |
| Revenue Next Year | $7.01 | $0.76 |
| P/E Ratio | $25.11 | ★ $24.87 |
| Revenue Growth | ★ 12.51 | N/A |
| 52 Week Low | $194.36 | $125.10 |
| 52 Week High | $335.83 | $228.29 |
Technical Indicators
Market Signals| Indicator | JLL | ICLR |
|---|---|---|
| Relative Strength Index (RSI) | 62.34 | 62.18 |
| Support Level | $319.74 | $174.13 |
| Resistance Level | $332.02 | $191.15 |
| Average True Range (ATR) | 9.52 | 8.46 |
| MACD | 1.62 | 2.87 |
| Stochastic Oscillator | 81.20 | 85.77 |
Price Performance
Historical ComparisonAbout JLL Jones Lang LaSalle Incorporated
Jones Lang LaSalle provides a wide range of real estate-related services to owners, occupiers, and investors worldwide, including leasing, property and project management, and capital markets advisory. JLL's investment management arm, LaSalle Investment Management, manages over $74 billion for clients across diverse public and private real estate strategies.
About ICLR ICON plc
Icon is a global late-stage contract research organization that provides drug development and clinical trial services to pharmaceutical, biotechnology, and medical-device firms. While the vast majority of its revenue comes from clinical research, Icon also offers ancillary services such as laboratory and imaging capabilities. The company is headquartered in Ireland.